Related Experiment Video
Updated: Aug 14, 2026
11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
9.9K
MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma
1Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Oncogene
|May 2, 2017
Summary
Vascular cell adhesion molecule-1 (VCAM-1) promotes monocyte adhesion to glioblastoma, driving tumor growth. Targeting the EGFR-VCAM-1 pathway offers a potential therapeutic strategy for glioblastoma multiforme (GBM).
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor-associated macrophages (TAMs) are crucial for glioblastoma multiforme (GBM) progression.
- Understanding monocyte-GBM interactions is key to identifying new therapeutic targets.
- Vascular cell adhesion molecule-1 (VCAM-1) mediates immune cell adhesion and is implicated in glioma pathogenesis.
Purpose of the Study:
- To investigate the role of VCAM-1 in monocyte recruitment to GBM.
- To elucidate the regulatory mechanisms of VCAM-1 expression in GBM.
- To explore VCAM-1 as a potential therapeutic target for GBM.
Main Methods:
- Analysis of glioma patient databases and immunohistochemistry.
- In vitro studies using 2D and 3D GBM cell cultures.
- Gene knockdown experiments and EGFR inhibition assays.
- Investigation of signaling pathways including miR-181, EGFR, p38/STAT3, and integrin α4β1.
Main Results:
- VCAM-1 expression positively correlates with glioma grade and monocyte adhesion.
- EGFR signaling drives VCAM-1 expression and subsequent monocyte adhesion.
- Monocyte adhesion via integrin α4β1 promotes GBM growth and invasion.
- miR-181b levels are inversely correlated with glioma grade and regulate VCAM-1 expression.
Conclusions:
- VCAM-1 is a critical mediator of EGFR-dependent monocyte recruitment in GBM.
- The EGFR-VCAM-1 axis represents a promising therapeutic target for GBM.
- Modulation of miR-181b may offer a novel strategy for GBM treatment.
